Prostate Cancer. Malignant neoplasm of prostate
Conditions
Interventions
Microrelin 3.75 milligram (Triptorelin which is LHRH agonist) each 28 days intramuscular
Produced by, PREMM Company of Italy
Imported by, Pooyesh Darou Company.
Treatment - Drugs
Microrelin 3.75 milligram (Triptorelin which is LHRH agonist) each 28 days intramuscular
Produced by, PREMM Company of Italy
Imported by, Pooyesh Darou Company
Sponsors
Vice chancellor for research Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients with metastatic prostate cancer without age limitation who are referred to urology clinic of Imam Khomeyni Hospital in 01.21.2014 until 01.21.2015 and accepted the term and condition of this study. Exclusion criteria: Reluctance of patients to continue the study or in case of death
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA. Timepoint: Before intervention, one month after intervention, three months after intervention and six months after intervention. Method of measurement: ELIZA.;Serum Testosterone. Timepoint: Before intervention, one month after intervention, three months after intervention and six months after intervention. Method of measurement: ELIZA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Loss of libido (Sexual desire was absent in all cases following castration) and Hot flash (As a subjective feeling of warmth in the head followed by objective perspiration, hot flashes are not life threatening but are among the most common side effects of androgen ablation). Timepoint: At every visit. Method of measurement: With history taking and physical exam. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactYonesian Masud
Vice chancellor for research, Tehran University Of Medical Sciences
Outcome results
None listed